DK297184A - Immunotoxin-konjugater til selektiv eliminering af cellepopulationer - Google Patents
Immunotoxin-konjugater til selektiv eliminering af cellepopulationer Download PDFInfo
- Publication number
- DK297184A DK297184A DK297184A DK297184A DK297184A DK 297184 A DK297184 A DK 297184A DK 297184 A DK297184 A DK 297184A DK 297184 A DK297184 A DK 297184A DK 297184 A DK297184 A DK 297184A
- Authority
- DK
- Denmark
- Prior art keywords
- cell populations
- selective elimination
- immunotoxin conjugates
- immunotoxin
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/54—Polycondensates of aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/819—Multifunctional antigen or antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Toxicology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/506,540 US4664911A (en) | 1983-06-21 | 1983-06-21 | Immunotoxin conjugates employing toxin B chain moieties |
Publications (2)
Publication Number | Publication Date |
---|---|
DK297184D0 DK297184D0 (da) | 1984-06-18 |
DK297184A true DK297184A (da) | 1984-12-22 |
Family
ID=24015007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK297184A DK297184A (da) | 1983-06-21 | 1984-06-18 | Immunotoxin-konjugater til selektiv eliminering af cellepopulationer |
Country Status (18)
Country | Link |
---|---|
US (1) | US4664911A (fr) |
EP (1) | EP0129434B1 (fr) |
JP (1) | JPH0639387B2 (fr) |
KR (1) | KR860001803B1 (fr) |
AT (1) | ATE46084T1 (fr) |
AU (1) | AU570049B2 (fr) |
CA (1) | CA1232838A (fr) |
DE (1) | DE3479633D1 (fr) |
DK (1) | DK297184A (fr) |
ES (2) | ES8604425A1 (fr) |
FI (1) | FI842420A (fr) |
GB (1) | GB2142032B (fr) |
GR (1) | GR82368B (fr) |
HU (1) | HUT34348A (fr) |
IL (1) | IL72117A0 (fr) |
PL (1) | PL248202A1 (fr) |
PT (1) | PT78752A (fr) |
ZA (1) | ZA844512B (fr) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925922A (en) * | 1983-02-22 | 1990-05-15 | Xoma Corporation | Potentiation of cytotoxic conjugates |
FR2550944B1 (fr) * | 1983-08-23 | 1985-12-06 | Sanofi Sa | Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
EP0232447A1 (fr) * | 1986-02-13 | 1987-08-19 | Xoma Corporation | Immunotoxines de lectine |
US6103243A (en) * | 1985-05-15 | 2000-08-15 | Biotechnology Australia Pty, Ltd | Oral vaccines |
US5283323A (en) * | 1985-08-07 | 1994-02-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing immune response |
DE3688137D1 (de) * | 1985-11-29 | 1993-04-29 | Consolidated Pharmaceuticals L | Ricin-antikoerper-konjugate. |
US4911911A (en) * | 1985-12-20 | 1990-03-27 | Sanofi | Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein |
FR2602682B1 (fr) * | 1986-08-12 | 1988-12-02 | Sanofi Sa | Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff |
US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
US5395924A (en) * | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
US5239062A (en) * | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
EP0261225B1 (fr) * | 1986-03-20 | 1995-09-27 | Dana-Farber Cancer Institute, Inc. | Complexe de lectine et sonde et procede de production |
US4806494A (en) * | 1986-07-24 | 1989-02-21 | The United States Of America As Represented By The Department Of Health & Human Services | Monoclonal antibody against ovarian cancer cells (OVB-3) |
FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
DE3751319T2 (de) * | 1986-10-09 | 1996-02-29 | Neorx Corp | VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN. |
US4808705A (en) * | 1986-12-19 | 1989-02-28 | Cetus Corporation | Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor |
US4962048A (en) * | 1987-02-19 | 1990-10-09 | Scripps Clinic & Research Foundation | Monoclonal antibodies to human pancreatic cancer |
US5320942A (en) * | 1987-02-19 | 1994-06-14 | Vito Quaranta | Method of diagnosing the presence of abnormal epithelial tissue using monoclonal antibodies to the A6 B4 cell surface protein |
US5981278A (en) * | 1987-05-29 | 1999-11-09 | Tanox, Inc. | Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS |
US6657050B1 (en) | 1987-05-29 | 2003-12-02 | Tanox, Inc. | Chimeric viral-neutralizing immunoglobulins |
US5834599A (en) * | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
CA1335227C (fr) * | 1987-06-22 | 1995-04-11 | Wylie W. Vale, Jr. | Analogues conjuges des recepteurs crf |
ZA89547B (en) * | 1988-02-02 | 1989-10-25 | Akzo Nv | Immunotoxins from barley toxin |
EP0407399A4 (en) * | 1988-02-03 | 1991-06-19 | Xoma Corporation | Immunosupression with anti-pan t-cell immunotoxin compositions |
US5827934A (en) * | 1988-03-08 | 1998-10-27 | The University Of Wyoming | Cytotoxic diphtheria toxin fragments |
JPH02503867A (ja) * | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Il‐2レセプター特異的キメラ抗体 |
US5149782A (en) * | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
US5045451A (en) * | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
US5621078A (en) * | 1989-03-22 | 1997-04-15 | Merck & Co., Inc. | Modified pseudomonas exotoxin PE40 |
US6207798B1 (en) | 1989-08-03 | 2001-03-27 | Merck & Co., Inc. | Modified PE40 toxin fusion proteins |
JPH05502218A (ja) * | 1989-09-14 | 1993-04-22 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 治療用組成物;hiv感染の治療方法 |
IL98528A0 (en) * | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
US5401243A (en) * | 1990-08-21 | 1995-03-28 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
WO1992007574A1 (fr) * | 1990-10-25 | 1992-05-14 | Tanox Biosystems, Inc. | Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
ATE153768T1 (de) * | 1991-01-15 | 1997-06-15 | Bayer Ag | Ergänzung von oberflächenrezeptoren |
ATE288923T1 (de) | 1991-02-08 | 2005-02-15 | Progenics Pharm Inc | Cd4-gamma2- und cd4-igg2-chimären |
US7070991B2 (en) | 1991-02-08 | 2006-07-04 | Progenics Pharmaceuticals, Inc. | Cells expressing a CD4-IgG2 chimeric heterotetramer |
US5112607A (en) * | 1991-06-05 | 1992-05-12 | The United States Of America As Represented By The Secretary Of The Army | Potentiation of immunotoxin action by Brefeldin A |
WO1993004191A1 (fr) * | 1991-08-15 | 1993-03-04 | Neorx Corporation | Conjugues de toxines non cytolytiques |
AU3583793A (en) * | 1992-01-24 | 1993-09-01 | Tanox Biosystems, Inc. | An immunotoxin including a cytotoxin with an unpaired cysteine residue in or near its receptor-binding site |
US5686072A (en) * | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
WO1994007138A1 (fr) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection de cellules cibles specifiques dans une population de cellules specialisees ou mixtes et solutions contenant des populations de cellules mixtes |
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
DE69429619T2 (de) | 1993-06-10 | 2002-09-12 | Allergan, Inc. | Behandlung von neuromusculaeren stoerungen und zustaenden mit botulism serotyp e |
US5876438A (en) * | 1993-08-02 | 1999-03-02 | Houston Biotechnology Incorporated | Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract |
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
AU688452B2 (en) | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
US5759546A (en) | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
NO180658C (no) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US5830478A (en) * | 1995-06-07 | 1998-11-03 | Boston Biomedical Research Institute | Method for delivering functional domains of diphtheria toxin to a cellular target |
US6497881B1 (en) * | 1995-11-30 | 2002-12-24 | New York University | High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
US6960652B2 (en) * | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
GB9909796D0 (en) * | 1999-04-28 | 1999-06-23 | Plant Bioscience Ltd | Pesticidal fumes |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US7838007B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
WO2002080849A2 (fr) * | 2001-04-06 | 2002-10-17 | University Of Chicago | Induction chimiotherapeutique de l'activite du promoteur egr-1 |
US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
US20030211470A1 (en) * | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
WO2004084816A2 (fr) * | 2003-03-21 | 2004-10-07 | Progenics Pharmaceuticals, Inc. | Formulations cd4-igg2 ameliorees |
EP1684785A4 (fr) * | 2003-11-14 | 2009-08-12 | Jay W Chaplin | Toxines ciblees lymphocytes b permettant de reduire une reponse immunitaire humorale |
US7358334B1 (en) | 2003-11-14 | 2008-04-15 | Jay W Chaplin | B cell-targeted toxins for humoral immune response reduction and methods of use thereof |
EP2468304A3 (fr) * | 2005-02-11 | 2012-09-26 | ImmunoGen, Inc. | Procédé de préparation de conjugués de médicaments stables |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
WO2006094539A1 (fr) * | 2005-03-03 | 2006-09-14 | Université Catholique de Louvain | Methodes et preparations de traitement du cancer |
WO2006110623A2 (fr) * | 2005-04-09 | 2006-10-19 | University Of Florida Research Foundation, Inc. | Toxine cholerique ciblee pour le traitement de la douleur persistante ou chronique |
SI1928503T1 (sl) | 2005-08-24 | 2012-11-30 | Immunogen Inc | Postopek za pripravo konjugatov majtansinoid protitelo |
WO2007109733A2 (fr) | 2006-03-21 | 2007-09-27 | The Johns Hopkins University | Marqueurs de diagnostic et de pronostic et strategies de traitement de la sclerose en plaques |
MX2010004488A (es) * | 2007-10-23 | 2010-06-17 | Allergan Inc | Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas. |
JP5805538B2 (ja) | 2008-11-07 | 2015-11-04 | リサーチ ディベロップメント ファウンデーション | Cripto/GSP78複合体形成およびシグナル伝達を阻害するための組成物および方法 |
TR201907573T4 (tr) | 2009-06-03 | 2019-06-21 | Immunogen Inc | Konjugasyon yöntemleri̇ |
KR20220009505A (ko) | 2011-03-29 | 2022-01-24 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
US10035817B2 (en) | 2012-10-04 | 2018-07-31 | Immunogen, Inc. | Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437213A1 (fr) * | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
JPS55136235A (en) * | 1979-04-09 | 1980-10-23 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5616417A (en) * | 1979-07-19 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5686121A (en) * | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
US4322495A (en) * | 1980-03-11 | 1982-03-30 | Minnesota Mining And Manufacturing Co. | Immunoassay |
EP0044167A3 (fr) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Agent cytotoxique dirigé par un anticorps |
US4359457A (en) * | 1980-09-30 | 1982-11-16 | Neville Jr David M | Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant |
US4440747A (en) * | 1980-09-30 | 1984-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease |
JPS5764617A (en) * | 1980-10-08 | 1982-04-19 | Teijin Ltd | Cytotoxic proteinic complex and its preparation |
US4397843A (en) * | 1980-10-23 | 1983-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Mannose-6-phosphate-low density protein reagent effective against hypercholesterolemia |
US4356117A (en) * | 1980-10-23 | 1982-10-26 | U.S. Govt., Dept. Of Health & Human Services | Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells |
JPS57106626A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
JPS57106625A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
FR2498192A2 (fr) * | 1981-01-22 | 1982-07-23 | Pasteur Institut | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
JPS5874614A (ja) * | 1981-10-30 | 1983-05-06 | Teijin Ltd | 蛋白複合体及びその製造法 |
FR2516794B1 (fr) * | 1981-11-20 | 1985-10-25 | Sanofi Sa | Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique |
FR2536997B1 (fr) * | 1982-03-11 | 1987-08-07 | Sanofi Sa | Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine |
FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
US4500637A (en) * | 1982-07-19 | 1985-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of graft versus host disease following bone marrow transplantation |
-
1983
- 1983-06-21 US US06/506,540 patent/US4664911A/en not_active Expired - Fee Related
-
1984
- 1984-06-14 ZA ZA844512A patent/ZA844512B/xx unknown
- 1984-06-14 FI FI842420A patent/FI842420A/fi not_active Application Discontinuation
- 1984-06-14 PL PL24820284A patent/PL248202A1/xx unknown
- 1984-06-14 GR GR75017A patent/GR82368B/el unknown
- 1984-06-15 PT PT78752A patent/PT78752A/pt not_active IP Right Cessation
- 1984-06-15 IL IL72117A patent/IL72117A0/xx unknown
- 1984-06-18 AU AU29480/84A patent/AU570049B2/en not_active Ceased
- 1984-06-18 ES ES533510A patent/ES8604425A1/es not_active Expired
- 1984-06-18 EP EP84304096A patent/EP0129434B1/fr not_active Expired
- 1984-06-18 DK DK297184A patent/DK297184A/da not_active Application Discontinuation
- 1984-06-18 DE DE8484304096T patent/DE3479633D1/de not_active Expired
- 1984-06-18 GB GB08415507A patent/GB2142032B/en not_active Expired
- 1984-06-18 CA CA000456816A patent/CA1232838A/fr not_active Expired
- 1984-06-18 AT AT84304096T patent/ATE46084T1/de active
- 1984-06-19 KR KR1019840003431A patent/KR860001803B1/ko not_active IP Right Cessation
- 1984-06-19 HU HU842360A patent/HUT34348A/hu unknown
- 1984-06-20 JP JP59127258A patent/JPH0639387B2/ja not_active Expired - Lifetime
-
1985
- 1985-07-03 ES ES544846A patent/ES8606884A1/es not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU2948084A (en) | 1985-01-03 |
DK297184D0 (da) | 1984-06-18 |
GR82368B (fr) | 1984-12-13 |
ES544846A0 (es) | 1986-04-16 |
KR850000248A (ko) | 1985-02-26 |
FI842420A0 (fi) | 1984-06-14 |
EP0129434A3 (en) | 1985-09-18 |
KR860001803B1 (ko) | 1986-10-23 |
ES533510A0 (es) | 1986-02-01 |
HUT34348A (en) | 1985-03-28 |
EP0129434A2 (fr) | 1984-12-27 |
JPS6069033A (ja) | 1985-04-19 |
JPH0639387B2 (ja) | 1994-05-25 |
PL248202A1 (en) | 1985-03-26 |
AU570049B2 (en) | 1988-03-03 |
DE3479633D1 (en) | 1989-10-12 |
ES8606884A1 (es) | 1986-04-16 |
ATE46084T1 (de) | 1989-09-15 |
US4664911A (en) | 1987-05-12 |
PT78752A (en) | 1984-07-01 |
GB2142032A (en) | 1985-01-09 |
GB2142032B (en) | 1987-05-13 |
EP0129434B1 (fr) | 1989-09-06 |
CA1232838A (fr) | 1988-02-16 |
GB8415507D0 (en) | 1984-07-25 |
FI842420A (fi) | 1984-12-22 |
ES8604425A1 (es) | 1986-02-01 |
ZA844512B (en) | 1986-02-26 |
IL72117A0 (en) | 1984-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK297184D0 (da) | Immunotoxin-konjugater til selektiv eliminering af cellepopulationer | |
IL71366A0 (en) | Immunoglobulin conjugates,their production and pharmaceutical compositions containing them | |
FR2382460A1 (fr) | Complexe antigene proteine pour bloquer les reactions allergiques | |
IT8322616A0 (it) | Composizione per agenti antitumorali. | |
TR200002345T2 (tr) | Glukokortikoit seçiçi antienflamatuar ajanlar | |
ES2104917T3 (es) | Bis-naftalimidas que contienen engarces amido y tioamido como agentes anticancerosos. | |
ES483662A1 (es) | Un procedimiento para la produccion de una 2-aminoetil-1-fe-nilindolina | |
IT8819746A0 (it) | Coniugati di immunoglobuline. | |
ES2063017T3 (es) | Anticuerpos monoclonales para antraciclinas. | |
DE68914356D1 (de) | Antikörper für die spezifische bindung an verbindungen. | |
ES1006677U (es) | Dispositivo con bridas deslizantes para anclar las vigas transversales de un andamio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AHB | Application shelved due to non-payment |